Kataoka K, Naomoto Y, Muro M, Kojima K, Horiki S, Hizuta A, Tanaka N, Orita K
First Dept. of Surgery, Okayama University Medical School.
Gan To Kagaku Ryoho. 1992 Mar;19(3):367-71.
Pirarubicin (THP) is a derivative of adriamycin (ADM) which has been reported to have a lower cardiotoxicity than ADM. The authors investigated the in vivo antitumor effect of THP against human colon cancer cells (RPMI 4788) xenografted into nude mice. In the model of intra-abdominal carcinomatosis, intraperitoneal administration of THP (6 mg/kg) resulted in a significant prolongation of the survival compared with the saline control group (p less than 0.01). Intravenous administration of THP (8 mg/kg) significantly inhibited tumor growth compared with the saline control group. Labeling index with bromodeoxyuridine (BrdU) of RPMI 4788 tumors treated with THP was smaller than that in the control group. Mitotic index was also smaller in the group treated with THP. Labeling index with BrdU indicates the proportion of cells in the S phase. Thus, the tumor cells in both S and M phases have decreased after treatment with THP. This change in the cell cycle progression may be due to the accumulation of G2 phase similar to in vitro study. From these results, it was suggested that the change in cell cycle progression revealed in vitro might be caused by THP in vivo.
吡柔比星（THP）是阿霉素（ADM）的衍生物，据报道其心脏毒性低于ADM。作者研究了THP对移植到裸鼠体内的人结肠癌细胞（RPMI 4788）的体内抗肿瘤作用。在腹腔内癌转移模型中，与生理盐水对照组相比，腹腔注射THP（6mg/kg）可显著延长生存期（p<0.01）。与生理盐水对照组相比，静脉注射THP（8mg/kg）可显著抑制肿瘤生长。用THP处理的RPMI 4788肿瘤的溴脱氧尿苷（BrdU）标记指数低于对照组。THP处理组的有丝分裂指数也较低。BrdU标记指数表示处于S期的细胞比例。因此，用THP处理后，处于S期和M期的肿瘤细胞均减少。细胞周期进程的这种变化可能是由于G2期的积累，类似于体外研究。从这些结果表明，体外观察到的细胞周期进程变化可能是由体内的THP引起的。
